Insider · CIK 0001679967
Jeffrey G. Lamothe
Files at APVO (Aptevo Therapeutics Inc.). First filing -, latest -.
In brief
Jeffrey G. Lamothe files SEC Form 4 as COO, CEO, president and director at APVO (Aptevo Therapeutics Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jeffrey G. Lamothe has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | APVO Aptevo Therapeutics Inc. | MOption exercise Common Stock | +961 | - | - | 961 | Aug 10, 2026 |
| Aug 6, 2026 | APVO Aptevo Therapeutics Inc. | MOption exercise Restricted Stock Unitderivative | -961 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Aug 6, 2025 | APVO Aptevo Therapeutics Inc. | AGrant or award Restricted Stock Unitderivative | +17,300 | $0.00 | $0 | 17,300 | Aug 8, 2025 |
| Jul 17, 2025 | APVO Aptevo Therapeutics Inc. | MOption exercise Common Stock (post-reverse split May ACTIVE) | +5 | - | - | 6 | Jul 21, 2025 |
| Jul 17, 2025 | APVO Aptevo Therapeutics Inc. | MOption exercise Restricted Stock Unitderivative | -5 | $0.00 | $0 | 12 | Jul 21, 2025 |
| Mar 2, 2025 | APVO Aptevo Therapeutics Inc. | MOption exercise Common Stock | +3 | - | - | 34 | Mar 4, 2025 |
| Mar 3, 2025 | APVO Aptevo Therapeutics Inc. | MOption exercise Common Stock | +2 | - | - | 36 | Mar 4, 2025 |
| Mar 2, 2025 | APVO Aptevo Therapeutics Inc. | MOption exercise Restricted Stock Unitderivative | -3 | $0.00 | $0 | 4 | Mar 4, 2025 |
| Mar 3, 2025 | APVO Aptevo Therapeutics Inc. | MOption exercise Restricted Stock Unitderivative | -2 | $0.00 | $0 | 0 | Mar 4, 2025 |
Questions about Jeffrey G. Lamothe
Answered from the filings on this page, as of the latest one.
Is Jeffrey G. Lamothe buying or selling?
Jeffrey G. Lamothe has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jeffrey G. Lamothe's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jeffrey G. Lamothe has 0.
Where does Jeffrey G. Lamothe file Form 4?
Jeffrey G. Lamothe has filed Form 4 at APVO (Aptevo Therapeutics Inc.) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.